Study of IBI363 in Patients with Advanced First-line Gastric Cancer

Exclusion Criteria

• •1. Women who are pregnant or lactating, or intending to become pregnant before, during, or within 6 months after the last dose of study drug.
• •2. Active uncontrolled bleeding or a known bleeding diathesis.
• •3. Subjects with history of or known active seizure disorder, brain metastases, spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease.